NTLA Q3 2020 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+109.3% YoY

Gross Profit

-$18M-78.9% margin

Operating Income

-$28M-126.5% margin

Net Income

-$28M-125.3% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+36.6%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$459M

Total Liabilities

$129M

Stockholders' Equity

$330M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$11M	+109.3%
Gross Profit	-$18M	-$17M	-3.8%
Operating Income	-$28M	-$25M	-11.0%
Net Income	-$28M	-$24M	-17.8%